SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following its inclusion as an awardee under the Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) program, signaling potential for significant defense contracts. This development, coupled with the stock's recent achievement of closing above a triple-digit price point, is fueling widespread community discussions about short squeeze potential and long-term growth for its direct-to-smartphone satellite technology.

Springview Holdings Ltd. engages in the design and construction of residential and commercial buildings. It involves new construction, reconstruction, alterations, and other general contracting services. The company was founded in 2002 and is headquartered in Singapore.

Springview Holdings Ltd - Ordinary Shares - Class A

Springview Holdings Ltd

Springview Holdings Ltd. (SPHL) is trending with explosive price action, largely driven by its low share float and a recently announced partnership for solar-ready homes in Singapore. The community is keenly comparing SPHL to other high-volatility microcap runners, actively discussing the potential for a significant short squeeze and parabolic gains.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a major talking point ahead of its upcoming earnings, with significant community debate swirling around a potential acquisition of Warner Bros. Discovery. Many anticipate a short squeeze and rebound, fueled by a new Sony Pictures content deal and unconfirmed rumors of Berkshire Hathaway's interest. However, others express concern over the WBD deal's financial implications and regulatory scrutiny, which they believe is heavily weighing on the stock, with investors keenly watching for management's clarity and earnings performance.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital (GLXY) is buzzing after securing ERCOT approval to double its Helios data center's power capacity to over 1.6 Gigawatts, fueling anticipation for major AI hyperscaler partnerships and a significant re-rating as an infrastructure play. The community is actively debating whether this landmark development will finally decouple the stock from Bitcoin's volatility and drive substantial analyst upgrades. While many see GLXY as a deeply undervalued AI and digital finance hybrid, some vocal skeptics remain frustrated by past performance and dilution concerns.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

Structure Therapeutics (GPCR) is generating significant buzz following impressive Phase 2b data for its oral GLP-1, Aleniglipron, which showcased notable weight loss and a compelling safety profile. Community discussion is intensely focused on the drug's potential as a best-in-class oral therapy, with many speculating a major pharmaceutical acquisition is highly probable, especially given the stock's recent strength and executive commentary.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as investors debate if its significant OpenAI investments are facing headwinds amid a broader tech pullback, leading to a notable share price decline. The community is actively discussing whether the stock is oversold and undervalued, while anticipating upcoming earnings for clarity on AI monetization and infrastructure costs. Many see current levels as a compelling long-term buying opportunity despite near-term volatility and frustration among existing holders.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as its J.P. Morgan Healthcare Conference presentation fuels intense shareholder debate. Many investors voice deep frustration over perceived management inaction and delayed partnerships for its flu/COVID combo and Matrix-M oncology applications. Amidst high short interest, the community eagerly anticipates a new major partnership or a potential proxy fight from major investor Shah Capital to unlock the company's valuation.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

BYTE CRYPTO is trending with intense community enthusiasm, driven by social media mentions and a strong 'pack' mentality. Investors are actively discussing its 'chosen one' status, often linking it to the AI meta and the 'Grok dog' narrative, highlighting its community-owned structure and perceived bullish sentiment.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

ProShares UltraPro QQQ is currently seeing heightened discussion amidst conflicting signals from tech earnings, particularly Oracle's recent miss and increased AI-related spending, alongside mixed labor data. Community sentiment is divided between those actively buying dips in anticipation of a potential Federal Reserve rate cut and a year-end rally, and others expressing caution over perceived market manipulation and stretched tech valuations. As a leveraged Nasdaq 100 ETF, TQQQ remains highly sensitive to these swings, prompting active debate on its short-term volatility versus its long-term growth potential within the evolving AI landscape.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending after its CEO signaled broad strategic interest in the company at a major healthcare conference, coinciding with a peer pharmaceutical CEO's remarks on significant M&A spending in the obesity sector. The community is actively debating the potential for a major partnership or acquisition, driven by recent positive clinical data for its lead weight-loss drug and its perceived strong profile. This positions VKTX as a key player in the rapidly expanding and competitive market for next-generation obesity treatments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Maze Therapeutics (NASDAQ:MAZE) CMO Sells 25,156 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 25,156 shares of the business's stock in a transaction dated Wednesday, January 7th. The stock was sold at an average...

Maze Therapeutics (NASDAQ:MAZE) CMO Harold Bernstein Sells 4,432 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 4,432 shares of the stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of...

Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells 412 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 412 shares of the company's stock in a transaction on Monday, January 5th. The stock was sold at an average price of...

Harold Bernstein Sells 4,432 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 4,432 shares of the business's stock in a transaction on Friday, January 2nd. The stock was sold at an average price...

Maze Therapeutics (NASDAQ:MAZE) SVP Amy Bachrodt Sells 5,000 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) SVP Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock in a transaction dated Friday, January 2nd. The stock was sold at an average...

Maze Therapeutics (NASDAQ:MAZE) Trading Down 4.9% - Here's Why

Maze Therapeutics (NASDAQ:MAZE) Trading Down 4.9% - Time to Sell...

Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells 45,000 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 45,000 shares of the company's stock in a transaction that occurred on Monday, December 29th. The shares were sold at...

Insider Selling: Maze Therapeutics (NASDAQ:MAZE) SVP Sells 5,000 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) SVP Amy Bachrodt sold 5,000 shares of the firm's stock in a transaction that occurred on Tuesday, December 30th. The stock was sold at an...

Amy Bachrodt Sells 10,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) SVP Amy Bachrodt sold 10,000 shares of the stock in a transaction dated Monday, December 29th. The stock was sold at an average price of...

Maze Therapeutics (NASDAQ:MAZE) Insider Sells $2,936,544.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Atul Dandekar sold 72,400 shares of Maze Therapeutics stock in a transaction that occurred on Monday, December 29th. The stock was sold...

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 29, 2017 and is headquartered in San Francisco, CA.

Maze Therapeutics Inc.

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$39.81
Prev Close	$41.11
Open	$41.30
Dividend Yield	N/A
50-Day Moving Average	$37.88
Beta	1.06
Avg. Volume	467,919.27
PE Ratio	-17.66

52-Week High	$43.29
52-Week Low	$6.71
Market Capitalization	$1.98B
EPS (Annual)	$0.0778
Price to Book	5.04
Revenue Per Employee	$1.34M
Enterprise Value/EBITDA	N/A

MAZE
Maze Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MAZE News

MAZEMaze Therapeutics Inc.